Vectura Share Discussion Threads

[sydney4] 04/2/2021 16:01

The fact that GSK can still appeal is in the public domain but the matter of their decision to appeal or not by the due date will need to be made public as and when. this would be material information in my opinion.

[polaris] 04/2/2021 13:25

An RNS is only required if there is a material difference to what is already in the public domain. That was all covered in the trading update so no need to update, as i said earlier (post 11000). I see IR have just backed up my assertion.

[gbcol] 04/2/2021 13:20

Just got a response from IR - basically says that there has been no change in the position set out in the January update and that they would have RNS’d if there had been a material change from what they had said then (i.e $164m to be paid by end Jan).

So can only assume money has been received but will have to wait until March update for confirmation on that - when we will also be well past the date GSK could have petitioned Supreme Court, so hopefully they can give us a steer on what they are going to do with it.

[gbcol] 04/2/2021 11:47

Have emailed Vectura IR twice for a response regarding receipt or not of the GSK payment. I even said I’d be happy enough if they confirm that they can’t comment but no response to either email, which is rather poor.

[jimboyce] 04/2/2021 11:42

Does seem a little fishy to me. Perhaps things are happening behind the scenes, but that may be wishful thinking on my part.

[sydney4] 04/2/2021 10:52

Not much to boast about until the appeal date has come and gone without any application ie the payment is absolute. One way or the other, would that not occasion an RNS - closed period or not?

[volvo] 04/2/2021 08:20

alord, yes it appears so, the company have missed another open goal imo to keep the pot bubbling, many other companies in a similar position would have boasted the fact that GSK had stumped up.

polaris no sales at Hikma re Advair to date is frustrating to all concerned.

March it is then

[polaris] 03/2/2021 18:38

No comment from GSK today regarding the loss of the litigation to VEC. In fact, the legal section on page 58 states that there were no significant legal developments in Q4 2020!

Ellipta US Q4 2020 sales are a bit of a disappointment. Seems GSK are moving people away to Nucala and Trelegy, neither of which has VEC IP.

Q4 US sales
Breo/Relvar £107 M
Anoro £90 M
Incruse £21 M

That's a total of £218 M and £6.5 M attributable to VEC. I was assuming £750 M in total sales up to IP expiry but now likely to be no more than £650 M.


Advair US sales in at £73M for the Q, down 30 % and the FY in at £434 M, down 14 %.

Still a decent market if Hikma can get the packaging issue quickly sorted.

[a1ord53] 02/2/2021 13:51

Volvo, will be no announcements until next results update on March 9th !
You was wrong !

[fhmktg] 02/2/2021 11:42

Thanks, just a couple of weeks until 17th...I can wait!

[polaris] 02/2/2021 11:25

The trading update stated the timeline and value of the GSK payment up to end Q3 2020. There is no reason to release an RNS as the data are already public domain. The only reasons to release a new RNS are if there are materially different amounts or timeline for the payment. AFAIK, VEC are in closed period and will only announce something that has a material impact beyond the trading statement.

[popper joe] 02/2/2021 10:43

Agree about the money and some confirmation that it has been transferred if that is the case. With regard to expiry of the appeal process; that is not until 90 days after the court judgement, which was 19th November. So if that is calendar days, that takes us to 17th Feb. So GSK still have freedom to appeal, but that does not preclude them from paying the monies by the end of January.

[fhmktg] 02/2/2021 10:19

Strange quiet on the GSK front.I would have thought any transfer of monies would require the market to be informed.Not even any update on the expiry of any appeal process by GSK.Any thoughts?

[ianood] 01/2/2021 15:12

Alice seems to be repeating herself :)

[gbcol] 01/2/2021 14:29

10991 I have now.

[sydney4] 01/2/2021 14:02

As Alice said. Curiouser and curiouser.

[sydney4] 01/2/2021 14:01

As Alice said. Curiouser and curiouser.

[sydney4] 01/2/2021 13:59

As Alice said. Curiouser and curiouser.

[justiceforthemany] 01/2/2021 13:01

Has anyone bothered to email the CEO or Investor Relations?

[gbcol] 01/2/2021 12:39

Maybe just making sure the cheque doesn’t bounce.

[volvo] 01/2/2021 10:18

Obviously the news of the GSK $164m hitting the bank account was not news worthy enough....thats if its arrived

[alexchry] 30/1/2021 15:46

...not as regards salary, perhaps something to do!

[diesel] 30/1/2021 13:01

This is starting to look as if the growth trend has stalled. If you allow for the GSK monies to be worth c20p, then underlying share price is around 100p. Tomorrow might bring all sorts of wonderous news but for now the management team are found wanting....

[volvo] 29/1/2021 19:30

yep its coming